Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis

被引:68
作者
Fennerty, MB
Johanson, JF
Hwang, C
Sostek, M
机构
[1] Oregon Hlth & Sci Univ, Div Gastroenterol, Portland, OR 97239 USA
[2] Rockford Gastroenterol Associates Ltd, Rockford, IL USA
[3] AstraZeneca LP, Wilmington, DE USA
关键词
D O I
10.1111/j.1365-2036.2005.02339.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Secondary analyses from previous studies indicated that esomeprazole was more effective than lansoprazole and omeprazole in healing moderate or severe (Los Angeles grades C or D) erosive oesophagitis (EE). Aim: To compare prospectively healing rates with esomeprazole vs. lansoprazole in patients with moderate to severe EE. Methods: In this multicentre, randomized, double-blind, parallel-group trial, adult patients with endoscopically confirmed moderate or severe EE received esomeprazole 40 mg (n = 498) or lansoprazole 30 mg (n = 501) once daily for up to 8 weeks. The primary end point was EE healing through week 8. Secondary assessments included investigator-assessed resolution of symptoms and safety and tolerability. Results: Time to healing was significantly different (P = 0.007), favouring esomeprazole. Estimated healing rates at week 8 were 82.4% with esomeprazole 40 mg and 77.5% with lansoprazole 30 mg. Heartburn resolved at week 4 in 72% and 64% of patients who received esomeprazole and lansoprazole, respectively (P = 0.005). Control of other GERD symptoms was similar between treatments. Both treatments were well tolerated. Conclusions: With 8 weeks' treatment, esomeprazole 40 mg once daily heals moderate to severe EE faster and in more patients, and resolves heartburn in more patients after 4 weeks of treatment, than lansoprazole 30 mg once daily.
引用
收藏
页码:455 / 463
页数:9
相关论文
共 23 条
[1]   Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole [J].
Andersson, T ;
Hassan-Alin, M ;
Hasselgren, G ;
Röhss, K ;
Weidolf, L .
CLINICAL PHARMACOKINETICS, 2001, 40 (06) :411-426
[2]  
BARDHAN KD, 1995, ALIMENT PHARM THERAP, V9, P145
[3]   ROLE OF GASTRIC-ACID SUPPRESSION IN THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE [J].
BELL, NJV ;
HUNT, RH .
GUT, 1992, 33 (01) :118-124
[4]  
Castell DO, 2002, AM J GASTROENTEROL, V97, P575
[5]  
Castell DO, 1996, AM J GASTROENTEROL, V91, P1749
[6]   Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis [J].
Chiba, N ;
DeGara, CJ ;
Wilkinson, JM ;
Hunt, RH .
GASTROENTEROLOGY, 1997, 112 (06) :1798-1810
[7]   An evidence-based appraisal of reflux disease management - the Genval workshop report [J].
Dent, J ;
Brun, J ;
Fendrick, AM ;
Fennerty, MB ;
Janssens, J ;
Kahrilas, PJ ;
Lauritsen, K ;
Reynolds, JC ;
Shaw, M ;
Talley, NJ .
GUT, 1999, 44 :S1-S16
[8]  
DeVault KR, 1999, AM J GASTROENTEROL, V94, P1434
[9]  
GREEN JRB, 1993, EUR J CLIN RES, V4, P29
[10]   LANSOPRAZOLE VERSUS OMEPRAZOLE IN SHORT-TERM TREATMENT OF REFLUX ESOPHAGITIS - RESULTS OF A SCANDINAVIAN MULTICENTER TRIAL [J].
HATLEBAKK, JG ;
BERSTAD, A ;
CARLING, L ;
SVEDBERG, LE ;
UNGE, P ;
EKSTROM, P ;
HALVORSEN, L ;
STALLEMO, A ;
HOVDENAK, N ;
TRONDSTAD, R ;
KITTANG, E ;
LANGE, OJ .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1993, 28 (03) :224-228